154 related articles for article (PubMed ID: 7908126)
21. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
22. Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice.
Czuczwar SJ; Borowicz KK; Kleinrok Z; Tutka P; Zarnowski T; Turski WA
Eur J Pharmacol; 1995 Aug; 281(3):327-33. PubMed ID: 8521917
[TBL] [Abstract][Full Text] [Related]
23. Competitive NMDA antagonists enhance the catalepsy induced by delta 9-tetrahydrocannabinol in mice.
Kinoshita H; Hasegawa T; Kameyama T; Yamamoto I; Nabeshima T
Neurosci Lett; 1994 Jun; 174(1):101-4. PubMed ID: 7970141
[TBL] [Abstract][Full Text] [Related]
24. Characterization of the glutamate receptors mediating release of somatostatin from cultured hippocampal neurons.
Fontana G; De Bernardi R; Ferro F; Gemignani A; Raiteri M
J Neurochem; 1996 Jan; 66(1):161-8. PubMed ID: 8522949
[TBL] [Abstract][Full Text] [Related]
25. The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
Maj J; Rogóz Z; Skuza G
J Neural Transm (Vienna); 1999; 106(11-12):1063-73. PubMed ID: 10651103
[TBL] [Abstract][Full Text] [Related]
26. Participation of AMPA- and NMDA-type excitatory amino acid receptors in the spinal reflex transmission, in rat.
Kocsis P; Tarnawa I; Szombathelyi Z; Farkas S
Brain Res Bull; 2003 Apr; 60(1-2):81-91. PubMed ID: 12725896
[TBL] [Abstract][Full Text] [Related]
27. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction.
Xue D; Huang ZG; Barnes K; Lesiuk HJ; Smith KE; Buchan AM
J Cereb Blood Flow Metab; 1994 Mar; 14(2):251-61. PubMed ID: 7509339
[TBL] [Abstract][Full Text] [Related]
28. AMPA antagonists differ from NMDA antagonists in their effects on operant DRL and delayed matching to position tasks.
Stephens DN; Cole BJ
Psychopharmacology (Berl); 1996 Aug; 126(3):249-59. PubMed ID: 8876025
[TBL] [Abstract][Full Text] [Related]
29. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain.
Kaur S; Ozer H; Starr M
Eur J Pharmacol; 1997 Aug; 332(2):153-60. PubMed ID: 9286616
[TBL] [Abstract][Full Text] [Related]
30. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
McAllister KH
Eur J Pharmacol; 1996 Oct; 314(3):307-11. PubMed ID: 8957251
[TBL] [Abstract][Full Text] [Related]
31. NMDA or AMPA/kainate receptor blockade prevents acquisition of conditioned place preference induced by D(2/3) dopamine receptor stimulation in rats.
Biondo AM; Clements RL; Hayes DJ; Eshpeter B; Greenshaw AJ
Psychopharmacology (Berl); 2005 Apr; 179(1):189-97. PubMed ID: 15744543
[TBL] [Abstract][Full Text] [Related]
32. State-dependent blockade of haloperidol-induced sensitization of catalepsy by MK-801.
Schmidt WJ; Tzschentke TM; Kretschmer BD
Eur J Neurosci; 1999 Sep; 11(9):3365-8. PubMed ID: 10510204
[TBL] [Abstract][Full Text] [Related]
33. GYKI 53665, a 2,3-benzodiazepine, non-competitively protects cultured neurones against AMPA toxicity.
Kovács AD; Szabó G
Eur J Pharmacol; 1997 Jul; 331(1):93-6. PubMed ID: 9274935
[TBL] [Abstract][Full Text] [Related]
34. Antagonism of AMPA receptors produces anxiolytic-like behavior in rodents: effects of GYKI 52466 and its novel analogues.
Kapus GL; Gacsályi I; Vegh M; Kompagne H; Hegedus E; Leveleki C; Hársing LG; Barkóczy J; Bilkei-Gorzó A; Lévay G
Psychopharmacology (Berl); 2008 Jun; 198(2):231-41. PubMed ID: 18363046
[TBL] [Abstract][Full Text] [Related]
35. Role of glutamate receptors in the development and maintenance of bladder overactivity after cerebral infarction in the rat.
Yokoyama O; Mizuno H; Komatsu K; Akino H; Tanase K; Namiki M
J Urol; 2004 Apr; 171(4):1709-14. PubMed ID: 15017271
[TBL] [Abstract][Full Text] [Related]
36. [Glutamate receptor antagonists attenuate experimental catalepsy in rats].
Rukoiatkina NI; Gorbunova LV; Gmiro VE; Lukomskaia NIa
Ross Fiziol Zh Im I M Sechenova; 2000 Jun; 86(6):626-33. PubMed ID: 10955300
[TBL] [Abstract][Full Text] [Related]
37. Modulation of kainate-induced responses by pentobarbitone and GYKI-53784 in rat abducens motoneurons in vivo.
Ruiz A; Durand J
Brain Res; 1999 Feb; 818(2):421-30. PubMed ID: 10082828
[TBL] [Abstract][Full Text] [Related]
38. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice.
Chapman AG; Smith SE; Meldrum BS
Epilepsy Res; 1991 Jul; 9(2):92-6. PubMed ID: 1794356
[TBL] [Abstract][Full Text] [Related]
39. The neuroprotective and hypothermic effect of GYKI-52466, a non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-antagonist on histological and behavioural variables in the gerbil global ischemia model.
Gyertyán I; Gigler G; Simó A
Brain Res Bull; 1999 Oct; 50(3):179-86. PubMed ID: 10566979
[TBL] [Abstract][Full Text] [Related]
40. Comparison of excitotoxic profiles of ATPA, AMPA, KA and NMDA in organotypic hippocampal slice cultures.
Kristensen BW; Noraberg J; Zimmer J
Brain Res; 2001 Oct; 917(1):21-44. PubMed ID: 11602227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
